thank you, ML. I read everything you post on NVAX and disagree with nothing.
I'm a physician who has been investing in biotech for 30 yrs and have learned over the years (sometimes the hard way) you are exactly right on this point. Moreover, BP won't give much value to anything not at least in Ph3. So, if a company can take their lead product to market without selling out, they will do much better in the long run; especially if they have a decent pipeline. Of course, that must be balanced against the go-it-alone risk that could leave owners poor if that lead drug gets tripped up. Sometimes one bird in the hand is better than ten in the bush. A classic fat tail dilemma.
Regarding old vaccine employees, what happened (in general) to Dean L? He was always great on the phone. gone fishing? another co?
Good early data in the 16mg/kg IV dose; once per week for the first 8 wks. The excitement is coming from a decent chance this (breakthrough) will allow them to market before ph3. The trial for the combo drug that includes Enhanze is not yet recruiting.,
Perhaps they go it alone with elderly and other at risk adult populations and partner for maternal and/or infant.
Don't go on margin and you'll be fine. The world turns and the tide comes back. Always.
Maybe. But, here's the thing. While you are making bets on what the stock market will do day to day, many here are making bets on what a certain company will do year to year. The general market will hardly matter to HALO shareholders in six months if Ph2 PEG results are good.
A decently knowledgeable biotech investor can make a more certain bet on a company (and a drug trial) than the world's best economist could ever make on the general market. And what chance do you or I have betting the larger market against the combined wisdom of the entire financial industry? In the end, such day trading is a loser's game.
Well, if you were short this week, you have done well. My investment strategies are buy and hold.
You have likely made your money off the EFT traders. Most who know this company well are holding for the long term. GLTU
I did, this AM. The buy is much higher than my average price, but the share price is much more likely to be 50% higher than 50% lower in six mos.
"anyone who owns this stock.." I own a ton.
What do you mean "they partnered PEGph20"? They have sold NO rights to the golden goose. they are simply allowing other companies to trial HALO's drug. What more could you want?
You are absolutely correct. Upon rejection, the bidding company could become "hostile" and make their bid known to the public. They would then try to enlist large shareholders in prevailing to the BOD to negotiate further.
Does anyone know if their shares were converted from preferred at the IPO or did they purchase them?
Also, why the ticker LIFE? Didn't that belong to a different, unrelated, company? A quick search of Yahoo's insider transactions shows data on a company run by Lucier Yahoo mistake, right?
....just doing my quarterly inspection of new cos and there is a lot here to intrigue. Seems expensive, though, and top heavy with management, for this stage of clinical development.
Thanks for sharing whatever you know.
correction: should read $180 million since leaving White House
My guess is that this is payback to him, from one of our hedgie backers, for other considerations.
Bill and Hillary earned $180 million in 2014. That didn't come from speaking engagements or her salary as Sec of State. Of course, Tom Ridge has many conections and a quality mind. But why a cancer biotech? Because someone like Adage, believes Mr Ridge can do very well here.
almost spit out my coffee laughing!
I was pondering what he brings as I read your comment.
Speaking to your valuation comment; I agree that efficacy should not be much of an issue. But it is easy to forget the other half of the equation, safety. Giving anything to pregnant women gives regulators the shivers. If the Ph3 shows any hint of any side effect, or there is any little difference in infant measures, approval could easily be side-tracked.
Some of the first users of an Ebola vaccine will be the health care workers who put their own lives in danger. They will be much easier to vaccinate with Merck's vaccine than the greater population,. So, WHO will push this through as fast as possible. Eventually, though, I agree that the cold storage issue will make it a secondary option.
That is my sense as well. It costs very little, relative to the total R&D budget, to keep insulin developing. Unlike the cellulite treatment, there is real potential for partnership someday with insulin. My bet is that Hylenex use in pumps will find a partner before PEG comes to market. It will be like found money.
I'm glad you got back into HALO. My advice would be to stay in :-)
ADXS is a fine company and I appreciated the head's up when it was single digits.
I have been loosely following Northwest for years, as their technology is good. I haven't looked at the recent presentations (maybe I will) but it takes much more than good technology to get me to buy. This isn't the place to post too much about that. Keep sending ideas, though. I try to look at everything. If I feel like getting into the fray about Northwest, I'll head on over to that board.
I was worried about you, Sudn. Your trade has been a disaster since you posted itt On June first. ADXS fell a third. HALO continues to climb.
I do like ADXS. I don't like NWBO - no cash. Limited partnerships. Both have good technology. Meanwhile, HALO has it all; great tech, path to market for PEG clear as day, loads of cash, increasing revenues, great management.